Nuplazid 34 MG capsule 30S
Ended Awarded
- Contract number
- SPE2DR26FCRE7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,589
Award facts
- Contract value 100% obligated
- $10,588.89 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,588.89 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). The delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.99 billion acquisition strategy designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, with demonstrated capability across diverse therapeutic categories including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's performance on numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division positions it effectively within the broader $30.3 billion PPV-G GEN V program, which operates through a 30-month base period with three 30-month option periods extending through December 31, 2036. This delivery order for Nuplazid, an antipsychotic medication, reflects the routine pharmaceutical supply operations supporting military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRE7?
SPE2DR26FCRE7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DR26FCRE7 worth?
The government has obligated $10,589 on SPE2DR26FCRE7.
Is contract SPE2DR26FCRE7 an order under another contract?
Yes. SPE2DR26FCRE7 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRE7 competed?
The extent of competition for SPE2DR26FCRE7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award